LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects.
OBJECTIVE
A recently published study showed the safety and efficacy of LSD-assisted psychotherapy in patients with anxiety associated with life-threatening diseases. Participants of this study were included in a prospective follow-up.


METHODS
12 months after finishing LSD psychotherapy, 10 participants were tested for anxiety (STAI) and participated in a semi-structured interview. A Qualitative Content Analysis (QCA) was carried out on the interviews to elaborate about LSD effects and lasting psychological changes.


RESULTS
None of the participants reported lasting adverse reactions. The significant benefits as measured with the STAI were sustained over a 12-month period. In the QCA participants consistently reported insightful, cathartic and interpersonal experiences, accompanied by a reduction in anxiety (77.8%) and a rise in quality of life (66.7%). Evaluations of subjective experiences suggest facilitated access to emotions, confrontation of previously unknown anxieties, worries, resources and intense emotional peak experiences à la Maslow as major psychological working mechanisms. The experiences created led to a restructuring of the person's emotional trust, situational understanding, habits and world view.


CONCLUSIONS
LSD administered in a medically supervised psychotherapeutic setting can be safe and generate lasting benefits in patients with a life-threatening disease. Explanatory models for the therapeutic effects of LSD warrant further study.
Medical Office for Psychiatry and Psychotherapy, Solothurn, Switzerland pgasser@gmx.net.
Peter
P
Gasser
Psychologist MSc, Dietikon, Switzerland.
Katharina
K
Kirchner
Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
Torsten
T
Passie
D000328:Adult; D001008:Anxiety Disorders / Q000150:complications / Q000523:psychology / Q000628:therapy*; D004311:Double-Blind Method; D004644:Emotions; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008238:Lysergic Acid Diethylamide / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications* / Q000523:psychology; D011613:Psychotherapy / Q000379:methods*; D036301:Qualitative Research; D011788:Quality of Life; D016896:Treatment Outcome
D008238:Lysergic Acid Diethylamide
LSD; hallucinogens; psychedelics; psycho-oncology; psycholytic therapy